ReviewFrontiers in pharmacology2017
Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Gut bacterial microbiome composition and statin intake-A systematic review.Pharmacology research & perspectives · 2020Pooled it
- Diet- and sex-related changes of gut microbiota composition and functional profiles after 4 months of weight loss intervention.European journal of nutrition · 2021Trial
- Trial
- A Novel Strain Bifidobacterium longum subsp. longum HN001 Ameliorates High-Fat Diet-Induced Obesity in Mice Through Microbiome-Associated Short-Chain Fatty Acids.Probiotics and antimicrobial proteins · 2026Article
- Identifying the location-dependent adipose tissue bacterial DNA signatures in obese patients that predict body weight loss.Gut microbes · 2025Article
- Deciphering the Physiological Responses to the Intake of Plant-Based Meat Analogues: On the Track of Microbiota and Biomarkers in Serum and Urine.Journal of agricultural and food chemistry · 2025Article
- Unraveling the gut microbiota's role in PCOS: a new frontier in metabolic health.Frontiers in endocrinology · 2025Review
- The global patent landscape of functional food innovation.Nature biotechnology · 2024Article
- Effects of Ginger (Biomolecules · 2024Review
- The Relationship between the Source of Dietary Animal Fats and Proteins and the Gut Microbiota Condition and Obesity in Humans.Nutrients · 2023Review
- Small intestinal microbiota composition altered in obesity-T2DM mice with high salt fed.Scientific reports · 2023Article
- Role of natural products and intestinal flora on type 2 diabetes mellitus treatment.World journal of clinical cases · 2023Review
- Microbial Phenolic Metabolites in Urine Are Inversely Linked to Certain Features of Metabolic Syndrome in Spanish Adolescents.Antioxidants (Basel, Switzerland) · 2022Article
- Dietary EVOO Polyphenols and Gut Microbiota Interaction: Are There Any Sex/Gender Influences?Antioxidants (Basel, Switzerland) · 2022Review
- Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer's disease.Natural products and bioprospecting · 2022Article
- Kidney Bean Fermented Broth Alleviates Hyperlipidemic by Regulating Serum Metabolites and Gut Microbiota Composition.Nutrients · 2022Article
- Integrated metagenomics and metabolomics analysis illustrates the systemic impact of the gut microbiota on host metabolism after bariatric surgery.Diabetes, obesity & metabolism · 2022Article
- Effect of detoxifiedJournal of animal science and technology · 2022Article
- Effects ofMicroorganisms · 2021Article
- Co-Encapsulated Synbiotics and Immobilized Probiotics in Human Health and Gut Microbiota Modulation.Foods (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 11 countries.
Funding
Abstract
Metabolic syndrome is a cluster of three or more metabolic disorders including insulin resistance, obesity, and hyperlipidemia. Obesity has become the epidemic of the twenty-first century with more than 1.6 billion overweight adults. Due to the strong connection between obesity and type 2 diabetes, obesity has received wide attention with subsequent coining of the term "diabesity." Recent studies have identified unique contributions of the immensely diverse gut microbiota in the pathogenesis of obesity and diabetes. Several mechanisms have been proposed including altered glucose and fatty acid metabolism, hepatic fatty acid storage, and modulation of glucagon-like peptide (GLP)-1. Importantly, the relationship between unhealthy diet and a modified gut microbiota composition observed in diabetic or obese subjects has been recognized. Similarly, the role of diet rich in polyphenols and plant polysaccharides in modulating gut bacteria and its impact on diabetes and obesity have been the subject of investigation by several research groups. Gut microbiota are also responsible for the extensive metabolism of polyphenols thus modulating their biological activities. The aim of this review is to shed light on the composition of gut microbes, their health importance and how they can contribute to diseases as well as their modulation by polyphenols and polysaccharides to control obesity and diabetes. In addition, the role of microbiota in improving the oral bioavailability of polyphenols and hence in shaping their antidiabetic and antiobesity activities will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.